• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.ESMO 临床研究观察站(ECRO):通过精简官僚主义提高临床研究效率。
ESMO Open. 2020 May;5(3):e000662. doi: 10.1136/esmoopen-2019-000662.
2
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.简化临床研究:提高临床试验赞助和监测的 ESMO 意识呼吁
Ann Oncol. 2023 Jan;34(1):70-77. doi: 10.1016/j.annonc.2022.09.162. Epub 2022 Oct 7.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
GCP data quality for early clinical development.药物临床试验质量管理规范数据的早期临床开发质量。
Clin Cancer Res. 2010 Mar 15;16(6):1756-63. doi: 10.1158/1078-0432.CCR-09-3267. Epub 2010 Mar 9.
5
Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety.实施 2009 年美国医学研究所关于住院医师工作时间、监督和安全的建议。
Nat Sci Sleep. 2011 Jun 24;3:47-85. doi: 10.2147/NSS.S19649. Print 2011.
6
Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle.良好意愿与国际人用药品注册技术协调会(ICH)- 药品临床试验质量管理规范(GCP):试验实施培训需要超越ICH - GCP文件,纳入意向性分析原则。
Clin Trials. 2014 Dec;11(6):629-34. doi: 10.1177/1740774514542620. Epub 2014 Jul 14.
7
Improving the quality conduct and efficiency of clinical trials with training: Recommendations for preparedness and qualification of investigators and delegates.通过培训提高临床试验的质量、实施和效率:对研究者和代表的准备和资格的建议。
Contemp Clin Trials. 2020 Feb;89:105918. doi: 10.1016/j.cct.2019.105918. Epub 2019 Dec 24.
8
European survey on national training activities in clinical research.欧洲临床研究国家培训活动调查。
Trials. 2019 Oct 29;20(1):616. doi: 10.1186/s13063-019-3702-z.
9
Guidelines, editors, pharma and the biological paradigm shift.指南、编辑、制药行业与生物学范式转变
Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.
10
Low-risk trials for children and pregnant women threatened by unnecessary strict regulations. Does the coming EU Clinical Trial Regulation offer a solution?低风险儿童和孕妇临床试验受到不必要的严格规定的威胁。即将出台的欧盟临床试验法规能否提供解决方案?
Eur J Pediatr. 2020 Aug;179(8):1205-1211. doi: 10.1007/s00431-020-03715-3. Epub 2020 Jun 13.

引用本文的文献

1
Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology.2019年冠状病毒病大流行对肿瘤学临床试验规范的影响。
Explor Target Antitumor Ther. 2023;4(5):1095-1103. doi: 10.37349/etat.2023.00183. Epub 2023 Oct 30.
2
RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study.改善致命疾病精准肿瘤学可及性的RAPID框架:一项改良多轮德尔菲研究的结果
Front Health Serv. 2023 Feb 27;3:1015621. doi: 10.3389/frhs.2023.1015621. eCollection 2023.
3
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.在全球启动III期试验的时间表:APHINITY试验的亚组分析。
Ecancermedicalscience. 2022 Apr 29;16:1379. doi: 10.3332/ecancer.2022.1379. eCollection 2022.
4
Reducing bureaucracy in clinical trials, now is the time!减少临床试验中的官僚作风,就是现在!
RMD Open. 2022 Feb;8(1). doi: 10.1136/rmdopen-2022-002202.
5
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.重塑大流行后时代的全球肿瘤学临床试验:战斗的号角。
JCO Glob Oncol. 2020 Sep;6:1357-1362. doi: 10.1200/GO.20.00346.
6
Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities.COVID-19 疫情期间的肿瘤学临床试验:危机期间的经验教训和未来机遇。
Cancer Treat Rev. 2020 Aug;88:102047. doi: 10.1016/j.ctrv.2020.102047. Epub 2020 Jun 10.

本文引用的文献

1
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.一项提前结束的国际多中心学术试验的探索性结果:RAVELLO,一项关于瑞戈非尼与安慰剂作为RAS野生型转移性结直肠癌一线治疗后维持治疗的III期研究。
ESMO Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. eCollection 2019.
2
Bureaucracy is strangling clinical research.官僚主义正在扼杀临床研究。
BMJ. 2019 Mar 13;364:l1097. doi: 10.1136/bmj.l1097.
3
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.合同研究组织官僚主义对临床试验管理的影响:以肺癌为例。
Clin Lung Cancer. 2018 Mar;19(2):191-198. doi: 10.1016/j.cllc.2017.10.012. Epub 2017 Oct 28.
4
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.为了患者的利益,保障欧洲独立学术性临床癌症研究的未来。
ESMO Open. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017.
5
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.扩大入选标准以使临床试验更具代表性:美国临床肿瘤学会与癌症研究之友联合研究声明
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.
6
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.现代化临床试验资格标准:美国临床肿瘤学会-癌症研究之友最低年龄工作组的建议
J Clin Oncol. 2017 Nov 20;35(33):3781-3787. doi: 10.1200/JCO.2017.74.4144. Epub 2017 Oct 2.
7
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.重新评估肿瘤学临床试验的资格标准:2015年研究性新药申请分析
J Clin Oncol. 2017 Nov 20;35(33):3745-3752. doi: 10.1200/JCO.2017.73.4186. Epub 2017 Oct 2.
8
Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.胸部肿瘤临床试验的入选标准和要求继续增加数量和复杂性。
J Thorac Oncol. 2017 Oct;12(10):1489-1495. doi: 10.1016/j.jtho.2017.07.020. Epub 2017 Aug 9.
9
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.简化癌症临床试验知情同意书的必要性。ARCAD集团立场文件。
Ann Oncol. 2017 May 1;28(5):922-930. doi: 10.1093/annonc/mdx050.
10
The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.晚期非小细胞肺癌患者临床试验分子检测面临的挑战:一项前瞻性数据库分析
Lung Cancer. 2016 Dec;102:96-100. doi: 10.1016/j.lungcan.2016.11.003. Epub 2016 Nov 6.

ESMO 临床研究观察站(ECRO):通过精简官僚主义提高临床研究效率。

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.

机构信息

Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, SpainPamplona, Spain.

Department of Oncology Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

出版信息

ESMO Open. 2020 May;5(3):e000662. doi: 10.1136/esmoopen-2019-000662.

DOI:10.1136/esmoopen-2019-000662
PMID:32393574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7223268/
Abstract

During the last years, there has been a dramatic increase in the administrative and bureaucratic burden associated with clinical research, which has clearly had an impact on its overall efficiency and on the activity of clinical investigators and research teams. Indeed, the supervision of the adherence of clinical research to Good Clinical Practice (GCP) guidelines and legal regulations is of the utmost importance. Yet, while such regulations have remained largely unchanged during recent years, the number of administrative tasks and their complexity have grown markedly, as supported by the results of a survey performed among 940 clinical investigators that we report in this manuscript. Therefore, many investigators believe that it has become necessary to undertake a rigorous analysis of the causes and consequences of this issue, and to create a conduit to channel the advice from experienced investigators regarding clinical research procedures, in order to improve them. Based on these premises, ESMO has launched the ESMO Clinical Research Observatory (ECRO), a task force that will analyse different aspects of clinical research. ECRO will aim to provide the views of ESMO on clinical research procedures based on the feedback from clinical investigators, under complete adherence to the Declaration of Helsinki, the GCP guidelines and any other applicable legal regulations, while at the same time showing profound respect for all the stakeholders involved in clinical research. This manuscript provides the background and rationale for the creation of ECRO, its planned activity and an analysis of the current administrative burden in clinical research with recommendations to rationalise it. Indeed, we expect that this effort shall lead to a relevant improvement in the care of patients and in the development of clinical research.

摘要

在过去的几年中,与临床研究相关的行政和官僚负担急剧增加,这显然对其整体效率以及临床研究者和研究团队的活动产生了影响。事实上,监督临床研究是否符合良好临床规范(GCP)指南和法律法规至关重要。然而,尽管近年来这些法规基本保持不变,但行政任务的数量及其复杂性明显增加,我们在本文报告的一项针对 940 名临床研究者的调查结果对此提供了支持。因此,许多研究者认为,有必要对这一问题的原因和后果进行严格分析,并建立一个渠道,将有经验的研究者关于临床研究程序的建议汇集起来,以改进这些程序。基于这些前提,ESMO 启动了 ESMO 临床研究观察站(ECRO),这是一个将分析临床研究不同方面的工作组。ECRO 将根据临床研究者的反馈,在完全遵守赫尔辛基宣言、GCP 指南和任何其他适用的法律法规的基础上,提供 ESMO 对临床研究程序的看法,同时对参与临床研究的所有利益相关者表示深切尊重。本文提供了创建 ECRO 的背景和基本原理、其计划活动以及对临床研究中当前行政负担的分析,并提出了合理化建议。事实上,我们期望这一努力将导致患者护理和临床研究的发展得到显著改善。